Maze Therapeutics (NASDAQ:MAZE - Get Free Report) was upgraded by stock analysts at Leerink Partnrs to a "strong-buy" rating in a research note issued to investors on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for Maze Therapeutics' Q4 2024 earnings at ($7.60) EPS, FY2024 earnings at ($4.93) EPS, Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($2.52) EPS, FY2028 earnings at ($2.72) EPS and FY2029 earnings at ($3.17) EPS.
MAZE has been the topic of a number of other reports. JPMorgan Chase & Co. initiated coverage on shares of Maze Therapeutics in a research note on Tuesday. They issued an "overweight" rating and a $30.00 target price on the stock. Leerink Partners initiated coverage on shares of Maze Therapeutics in a research note on Tuesday. They issued an "outperform" rating and a $28.00 target price on the stock. Finally, Guggenheim initiated coverage on shares of Maze Therapeutics in a research note on Tuesday. They set a "buy" rating and a $19.00 price target on the stock. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $25.67.
Get Our Latest Analysis on MAZE
Maze Therapeutics Stock Down 3.9 %
MAZE traded down $0.49 on Tuesday, reaching $12.23. The company had a trading volume of 141,658 shares, compared to its average volume of 324,193. Maze Therapeutics has a 52-week low of $10.08 and a 52-week high of $17.00.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Articles
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
